Prognostic markers in core‐binding factor AML and improved survival with multiple consolidation cycles of intermediate‐/high‐dose cytarabine

• DOI: 10.1111/ejh.13089
• Publication Date: 2018-05-02T23:48:42Z
• Authors: Ashvind Prabahran; Mark Tacey; Shaun Fleming; Andrew Wei; Courtney Tate; Paula Marlton; Joel Wight; Andrew Grigg; Annabel Tuckfield; Jeff Szer; David Ritchie; Lynette Chee
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 610; 3. Good health

Abstract Objectives Core‐binding factor acute myeloid leukaemia ( CBF AML ) defined by t (8;21)(q22;q22) or inv(16)(p13q22)/ (16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for in de novo cohort. Patients/Materials/Methods A retrospective review from four Australian tertiary centres 2001 2012, comprising 40 (8;21) and 30 inv(16) s. Results Multivariate analysis identified age P = .032) white cell count WCC )>40 .025) as significant predictors inferior OS relapse, respectively. Relapse was higher group vs (57% 18%, HR 4.31, 95% CI : 1.78‐10.42, .001). Induction therapy had no bearing on relapse‐free survival RFS ); consolidation treatment with >3 cycles intermediate‐/high‐dose cytarabine improved .035) .063). Five demonstrated post‐treatment stable q PCR positivity without relapse. Conclusions improves patient outcomes Age subtype are , Stable low‐level MRD qPCR does not predict Similar cohort compared cohort, despite rate, confirms salvageability relapsed disease.